Iovance Biotherapeutics Announces April Scientific and Investor Presentations
March 29 2019 - 8:23AM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage
biotechnology company developing novel cancer immunotherapies based
on tumor-infiltrating lymphocyte (TIL) technology, today announced
that the company will present at the following conferences in
April:
- American Association for Cancer Research (AACR) Annual
Meeting in Atlanta, March 29-April 3Title: Persistence of
cryopreserved tumor-infiltrating lymphocyte product lifileucel
(LN-144) in C-144-01 study of advanced metastatic melanomaAuthors:
Viktoria Gontcharova et al.Session Title: Late-Breaking Research:
Immunology 1Session Type: Late-Breaking Poster SessionSection:
41Abstract Number: LB-069Location: Georgia World Congress
CenterDate/Time: Monday, April 1, from 8:00 a.m. - 12:00 p.m.
EDT
- Jefferies 6th Annual IO Cell Therapy Summit in
Boston, April 5Location: Boston Harbor HotelDate/Time: Friday,
April 5, at 10:35 a.m. EDT
- HC Wainwright Global Life Science Conference
in London, April 7-9Location: JW Marriott Grosvenor House
LondonDate/Time: Tuesday, April 9, at 9:50 a.m. BSTA live and
archived webcast of the presentation will be available by visiting
the Investors section of the Iovance Biotherapeutics website at
http://ir.iovance.com.
- 2019 Cell & Gene Meeting on the
Mediterranean in Barcelona, April 23-25Location: Hotel
Arts BarcelonaDate/Time: Wednesday, April 24, at 12:00 p.m.
CEST
- 15th European Association of Dermato-Oncology (EADO)
Congress in Paris, April 24-27Title: Safety and
efficacy of cryopreserved autologous tumor infiltrating lymphocytes
(LN-144, lifileucel) in previously treated metastatic melanoma
patients (Encore presentation)Location: Maison de la Chimie
Conference CenterDate/Time: Thursday, April 25 at 2:07 p.m.
CEST
About Iovance Biotherapeutics,
Inc. Iovance Biotherapeutics intends to commercialize
autologous cell therapy using tumor-infiltrating lymphocyte (TIL)
technology that amplifies the body’s own immune response to
eradicate solid tumors or attack blood cancers. The company is
currently conducting the pivotal study innovaTIL-01 in patients
with metastatic melanoma. In addition, the company’s TIL therapies
are being investigated for the treatment of patients with locally
advanced, recurrent or metastatic cancers including cervical, head
and neck, and non-small cell lung cancer. For more information,
please visit www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release
are “forward-looking statements” of Iovance Biotherapeutics, Inc.
(hereinafter referred to as the “Company,” “we,” “us,” or “our”).
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. The forward-looking
statements include, but are not limited to, risks and uncertainties
relating to the success, timing, projected enrollment,
manufacturing capabilities, and cost of our ongoing clinical trials
and anticipated clinical trials for our current product candidates
(including both Company-sponsored and collaborator-sponsored trials
in both the U.S. and Europe), such as statements regarding the
timing of initiation and completion of these trials; the timing of
and our ability to obtain and maintain U.S. Food and Drug
Administration or other regulatory authority approval of, or other
action with respect to, our product candidates; the strength of
Company’s product pipeline; the successful implementation of the
Company’s research and development programs and collaborations; the
success of the Company’s manufacturing, license or development
agreements; the acceptance by the market of the Company’s product
candidates, if approved; and other factors, including general
economic conditions and regulatory developments, not within the
Company’s control. The factors discussed herein could cause actual
results and developments to be materially different from those
expressed in or implied by such statements. Actual results
may differ from those set forth in this press release due to the
risks and uncertainties inherent in the Company’s business,
including, without limitation; the preliminary clinical results,
including efficacy and safety results, from ongoing Phase 2 studies
may not be reflected in the final analyses of these trials,
including new cohorts within these trials, and may not be
supportive of product approval; the FDA or other regulatory
authorities may potentially delay the timing of their approval of,
or other action with respect to, the Company’s product candidates;
the Company’s ability to address FDA or other regulatory authority
requirements relating to its clinical programs and registrational
plans, such requirements including, but not limited to, clinical
and safety requirements as well as manufacturing and control
requirements; risks related to the Company’s accelerated FDA review
designations; and the ability of the Company to manufacture its
therapies using third party manufacturers. A further list and
description of the Company’s risks, uncertainties and other factors
can be found in the Company’s most recent Annual Report on Form
10-K and the Company's subsequent filings with the Securities and
Exchange Commission. Copies of these filings are available online
at www.sec.gov or www.iovance.com. The forward-looking statements
are made only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.
Investor Relations
Contacts: Annie ChangSolebury
Trout646-378-2972achang@troutgroup.com
Chad RubinSolebury
Trout646-378-2947crubin@troutgroup.com
Media Relations Contact: Rich
AllanSolebury Trout646-378-2958rallan@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024